Nicotinamide Adenine Dinucleotide Market Report 2026

The nicotinamide adenine dinucleotide market size has grown rapidly in recent years. It will grow from $5.59 billion in 2025 to $6.48 billion in 2026 at a compound annual growth rate (CAGR) of 16.1%. The growth in the historic period can be attributed to increasing demand for anti-aging supplements, growing research on cellular metabolism, rising awareness of preventive healthcare, expansion of nutraceutical distribution channels, increasing adoption of wellness and biohacking products.

The nicotinamide adenine dinucleotide market size is expected to see rapid growth in the next few years. It will grow to $11.65 billion in 2030 at a compound annual growth rate (CAGR) of 15.8%. The growth in the forecast period can be attributed to growing consumer spending on longevity and vitality solutions, increasing adoption of nad precursors in mainstream supplements, rising expansion of IV therapy and regenerative clinics, increasing pharmaceutical interest in nad for chronic disease management, expanding penetration of online personalized supplement programs. Major trends in the forecast period include technology advancements in sustained-release and liposomal delivery formats, innovations in multi-ingredient longevity formulations, developments in nad-based dermatology and skincare actives, research and developments in therapeutic-grade nad for neurological and metabolic disorders, advancements in biomarker-based personalized supplementation platforms.

The increasing prevalence of age-related and metabolic disorders is expected to drive the growth of the nicotinamide adenine dinucleotide (NAD⁺) market in the coming years. Age-related and metabolic disorders include conditions such as diabetes, obesity, cardiovascular diseases, and neurodegenerative disorders, which are linked to aging, impaired metabolism, and cellular dysfunction. Their prevalence is rising due to aging populations and the widespread adoption of unhealthy lifestyle patterns, including sedentary behavior, excessive calorie intake, and increasing obesity rates. NAD⁺ supports the management of these disorders by playing a key role in cellular energy metabolism, mitochondrial function, and DNA repair processes, which are essential for maintaining metabolic health and mitigating age-associated cellular decline. For example, in February 2025, the International Diabetes Federation, a Belgium-based nonprofit representing diabetes associations worldwide, projected that the number of people over 65 years with diabetes would reach 195.2 million (19.6%) by 2030 and 276.2 million by 2045, highlighting a significant increase in diabetes burden in aging populations with major public health and economic implications. Consequently, the rising prevalence of age-related and metabolic disorders is fueling the growth of the NAD⁺ market.

Leading companies in the nicotinamide adenine dinucleotide (NAD⁺) market are focusing on developing advanced formulations, such as NAD⁺ skincare supplements, to support anti-aging and enhance skin health. NAD⁺ skincare supplements are dietary or topical products designed to boost NAD⁺ levels in skin cells, promoting cellular energy, repair, and anti-aging processes to improve skin health and appearance. For example, in November 2025, ChromaDex Corporation, a US-based NAD⁺ bioscience company, launched Tru Niagen Beauty, the first NAD⁺ skincare supplement available in the United States. The product features a precision blend of clinically studied ingredients, including its patented nicotinamide riboside (Niagen), aimed at supporting cellular energy production, skin health, and overall wellness by increasing NAD⁺ availability, which naturally declines with age.

In October 2023, L Catterton Management Company LLC, a US-based consumer-focused investment firm, acquired Thorne HealthTech Inc. for an undisclosed sum. This acquisition allowed L Catterton to expand its presence in the personalized wellness and longevity-focused nutrition markets by leveraging Thorne’s established product portfolio, research and development capabilities, and direct-to-consumer reach. Thorne HealthTech Inc. is a US-based nutritional supplement company specializing in nicotinamide adenine dinucleotide (NAD)-related health products.

Major companies operating in the nicotinamide adenine dinucleotide market are Thermo Fisher Scientific Inc., Life Extension Foundation Buyers Club Inc., Niagen Bioscience Inc., Tokyo Chemical Industry Co. Ltd., Otto Chemie Pvt. Ltd., HiMedia Laboratories Pvt. Ltd., Sichuan Benepure Pharmaceutical, F. Hoffmann-La Roche Ltd, Herbalmax Ltd., Nuray Chemicals Private Limited, Hefei Home Sunshine Pharmaceutical Technology Co. Ltd., Syncozymes Biotechnology Co. Ltd., OYC Americas Inc., Xi’an Yinherb Bio-Tech Co. Ltd., Shenzhen Hygieia Biotechnology Co. Ltd., Zhejiang Dazhan Biotechnology Co. Ltd., Willow Birch Pharma Inc., Hubei AOKS Bio-Tech Co. Ltd., Shanghai Neutan Pharmaceutical Co. Ltd., Evereen (Shanghai) Biotechnology Co. Ltd.

North America was the largest region in the nicotinamide adenine dinucleotide market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nicotinamide adenine dinucleotide market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nicotinamide adenine dinucleotide market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs are impacting the nicotinamide adenine dinucleotide market by increasing costs of imported pharmaceutical-grade raw materials, biochemical intermediates, encapsulation inputs, and sterile processing equipment used in supplement and infusion product manufacturing. north america and europe are most affected due to dependence on imported active ingredients and specialized processing technologies, while asia-pacific faces cost pressure on export-oriented production. these tariffs are raising product prices and compliance costs across dietary supplement, pharmaceutical, and cosmetic segments. however, they are also encouraging localized production, regional sourcing of precursors, and increased investment in domestic biomanufacturing capabilities.

Nicotinamide adenine dinucleotide (NAD⁺) is an essential coenzyme present in all living cells that plays a crucial role in cellular metabolism. It primarily acts as an electron carrier in redox reactions, facilitating the conversion of nutrients into energy by transferring electrons in processes such as glycolysis, the citric acid cycle, and oxidative phosphorylation. Additionally, NAD⁺ is involved in DNA repair, regulation of gene expression, and cell signaling.

The primary product types of nicotinamide adenine dinucleotide (NAD) include oral nicotinamide adenine dinucleotide supplements, nicotinamide adenine dinucleotide and NADH direct-ingredient capsules, nicotinamide adenine dinucleotide injection and infusion products, specialized anti-aging and metabolic formulations, nicotinamide adenine dinucleotide precursors, and topical and cosmetic nicotinamide adenine dinucleotide formulations. Oral nicotinamide adenine dinucleotide supplements refer to orally administered products that deliver nicotinamide adenine dinucleotide or its precursors to support cellular energy metabolism, healthy aging, and overall wellness. The various grades include food grade, pharmaceutical grade, and others. The distribution channels include online and e-commerce and offline channels. The applications include dietary supplements and wellness, pharmaceuticals and therapeutics, cosmetics and dermatology, clinical IV therapy, regenerative medicine, and research and biotechnology, and the key end users include individual consumers, healthcare providers, and pharmaceutical companies.

The nicotinamide adenine dinucleotide market consists of sales of NAD⁺ supplements, NADH formulations, nicotinamide riboside (NR) products, nicotinamide mononucleotide (NMN) products, and related nutraceuticals and functional foods. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.